ReviewClinical kidney journal2025
Management of osteoporosis in chronic kidney disease.
Review in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Computed tomography-measured trabecular attenuation at first lumbar vertebra as a surrogate marker of bone mineral density and osteoporosis in patients undergoing hemodialysis.Renal failure · 2026Article
- Mineral and Bone Disease in CKD and Kidney Transplantation: Controversies, Gaps, and a Path Forward.Kidney international reports · 2026Review
- Fragility fractures and risk factors in a peritoneal dialysis setting.Archives of osteoporosis · 2026Article
- Combination of Biomarkers and Novel Diagnostic Tools in the Management of Osteoporosis in Chronic Kidney Disease: An Update.Journal of clinical medicine · 2026Review
- Cardiovascular Disease and Fracture Risk in People with Type 2 Diabetes: A Nationwide Matched Case-Control Study.Calcified tissue international · 2026Article
- High fracture risk, limited evidence: rethinking osteoporosis treatment in chronic kidney disease.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with chronic kidney disease (CKD) face an excessive burden of bone disease and fracture risk compared with the general population due to metabolic derangements related to renal disease as well as traditional fracture risk factors, osteoporosis and advancing age. Fragility fracture incidence increases with progressive renal impairment and age, and fractures in this group are associated with exaggerated morbidity and mortality. Despite this, the diagnosis and management of osteoporosis in CKD is not well understood and patients are frequently undertreated. This review summarises the current understanding of and recommendations for the diagnosis and management of osteoporosis in CKD and provides a pragmatic approach to fracture risk assessment and reduction in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.